Clinical Trial Update: Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing dermal irritation, sensitization, and cumulative irritation potential of 6% bemotrizinol in subjects with sunburn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sunburn

Drugs mentioned

• bemotrizinol (bemotrizinol)

Snippet

Sponsor: dsm-firmenich Switzerland AG | Conditions: Sunburn | Phase 2 | Status: COMPLETED